Motif Bio Share Discussion Threads

[parob] 22/9/2017 12:06

If the 1725000 was the last batch then we're clear to head north.

[encarter] 22/9/2017 11:59

AMP know this is a winner but have no choice but to sell stock.

[bean02] 22/9/2017 11:53

Cleared for take off now!

[t-trader] 22/9/2017 11:48

1.725m sell (most likely AMP), probably what has been holding us back the past few days. Hopefully see a rerate from here.

I know AMP need to raise cash, but I think they will be kicking themselves months from now.

[t-trader] 22/9/2017 11:35

I really am amazed at how low the mcap is here considering at what stage the company is at. £86m with R2 results just around the corner and if they follow R1 as expected then we should easily be twice that.

[someuwin] 20/9/2017 19:37

Listening to the presentation webcast - very good so far.

[philoosh] 20/9/2017 16:31

Fingers crossed it takes off. I've topped up and I've got no money left to buy any more.

[someuwin] 20/9/2017 15:02

Vox Markets Podcast‏ @VoxPodcast · 6 minutes ago

On the podcast Graham Lumsden of #MTFB on iclaprim's Orphan Drug Designation grant for patients with CF>

[adorling] 20/9/2017 14:54

Up 7.4% today says it may have already started philosophy!

[pyglet] 20/9/2017 14:48

December IMO

[philoosh] 20/9/2017 14:45

How soon is it likely to skyrocket? This year?

[someuwin] 20/9/2017 13:31

Looking to head back to 70p + soon...

[pyglet] 20/9/2017 13:25

added more - momentum with us now - looking to head back to 40p + soon

[someuwin] 20/9/2017 13:16

Just a reminder...

"Motif Bio to Host Investor and Analyst Event on September 20, 2017 in New York

Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announces that the Company will host an Investor and Analyst Event on Wednesday, September 20, 2017, in New York from 8:00 am - 10:00 am ET, 1.00pm - 3.00pm UK time, 2.00pm-4.00pm CET.

The event will focus on describing the unmet needs of hospitalised patients with serious and life-threatening infections and highlight the key attributes of iclaprim that, if approved, may offer advantages over current standard of care antibiotics in three well-defined groups of patients.

A faculty of infectious disease experts and Motif Bio senior management will describe the clinical and economic challenges that can lead to poor outcomes in high-risk, difficult-to-treat hospitalised patients with serious infections. The potential role that iclaprim can play in these patients will be described.

The agenda will include:

Introduction

Graham G. Lumsden, Chief Executive Officer, Motif Bio

Iclaprim Overview & REVIVE-1 (Ph. 3) Results

David Huang, PhD, MD, Chief Medical Officer, Motif Bio

William D. O'Riordan, MD, FACEP, Chief Medical Officer, eStudySite, San Diego, CA

HABP Treatment Considerations & Unmet Needs

Thomas M. File, Jr., MD, MSc, MACP, FIDSA, FCCP Chair, Infectious Disease Division, Summa Health, Akron, OH

Challenges in Managing Hospitalised ABSSSI Patients with Renal Impairment

Francis Natale, PharmD, Director of Pharmacy, Methodist Hospital Division, Thomas Jefferson University Hospitals, Philadelphia, PA

Thomas Holland, MD, MSc-GH, Duke University School of Medicine & Clinical Research Institute, Durham, NC

Economic Burden of High Risk Hospitalised ABSSSI Patients

Tom Lodise, PhD, PharmD, Albany College of Pharmacy & Health Sciences, Albany, NY

Commercial Market Opportunity

Lynda Berne, M.S., M.B.A., Commercial Head, Motif Bio

If you are a member of the investment community and would like to attend, please contact [e-mail].

The presentation will be webcast simultaneously and accessible through the Investors - Events & Presentations section of the Company's website at www.motifbio.com. A webcast replay, including slides, will be available for 30 days following the event."

[parob] 20/9/2017 13:15

Have been watching and waiting for the breakout. Have just joined you guys with a decent stake! Looks like the seller has cleared. GLA!

[t-trader] 20/9/2017 12:50

I wonder how many big Pharma's have motif on there radar. Surely must be in the watchful eye of a few.

[t-trader] 20/9/2017 12:08

....and deservedly so. Hopefully see more momentum following New York investor meeting.

[someuwin] 20/9/2017 11:37

The trend is definitely upwards now.

[timbo003] 20/9/2017 09:17

The CF development sounds exciting

I am unable to tune in to the live web cast today, so hoping there will be a replay available

[small crow] 15/9/2017 18:09

I don't think AMP will sell until day before loan payment due!

[encarter] 15/9/2017 16:48

It looks to me like someone has some stock for sale, probably AMP. Once it clears. Whoosh!

[ianb5004] 15/9/2017 15:37

Friday afternoon most in the pub. Monday would have ben better but ii suppose weekend press may get hold of it.

[brucie5] 15/9/2017 15:08

Market seems either unimpressed or slow to see this. So I've taken a few more. And that really is my lot!

[ianb5004] 15/9/2017 14:49

Fda are clearly backing Iclaprim. Great news today and bodes very well for approval.